Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

With JBCHEPHARM's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 29.881266
debtToEquity 3.120000
earningsGrowth 0.210000
revenueGrowth 0.141000
grossMargins 0.653460
operatingMargins 0.220630
trailingEps 40.240000
forwardEps 0.000000

JBCHEPHARM's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
J. B. Chemicals & Pharmaceuticals Limited's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as J. B. Chemicals & Pharmaceuticals Limited's increasing profits and sales signal further growth in the near future.
JBCHEPHARM's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM



Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


40 transactions were made to sell JBCHEPHARM shares, with market price of 1792.8487548828125.There were no sell transactions during the given timeframe.The recent trend of more purchases than sales at JBCHEPHARM's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


With analysts showing a buy bias for J. B. Chemicals & Pharmaceuticals Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning J. B. Chemicals & Pharmaceuticals Limited as a safe and profitable place for investors to allocate their funds and seek growth.